Sanofi expects RSV antibody to ⁠breach blockbuster status in 2024, even as supply hitch drags on

As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial immunization rollout with partner AstraZeneca. On both fronts, Sanofi expects to see dividends in 2024.